학술논문
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
Document Type
Article
Author
Source
In: Antiviral Therapy . (Antiviral Therapy, 2015, 20(3):343-348)
Subject
Language
English
ISSN
20402058
13596535
13596535